Holen Sie sich die Stockscreener-App
3.30
3.79%
-0.13
Handel nachbörslich:
3.28
-0.02
-0.61%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Analyst sentiment remains strong on Iovance Biotherapeutics (IOVA) amid US rollout of melanoma drug, Amtagvi - MSN
IOVA SEC FilingsIovance Biotherp 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today? - Meyka
Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed? - Sahm
Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote, News & History - Benzinga
Why is Iovance Biotherapeutics Inc stock going up2026 Final Week & Real-Time Chart Breakout Alerts - baoquankhu1.vn
IOVA Earnings History & Surprises | EPS & Revenue Results | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After FDA Concerns Over Amtagvi Marketing Practices - Sahm
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - msn.com
Proleukin Market Research Report 2026-2035: Epidemiology, Pipeline Analysis, Industry Insights and More - GlobeNewswire Inc.
After IOVA stock’s best day in 2 years, analyst sees over 300% upside: Here’s why - MSN
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA) - Seeking Alpha
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Sahm
Market Outlook: Is Iovance Biotherapeutics Inc a stock for growth or value investors2026 Buyback Activity & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Volume Recap: Is Iovance Biotherapeutics Inc still a buy after recent gains2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
IOVA | Iovance Biotherapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics (MIL:1IOVA) NonCurrent Deferred Rev - GuruFocus
Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Iovance downgraded to Neutral at UBS related to Amtagvi concerns - MSN
Q2 2025 Iovance Biotherapeutics Inc Earnings Call Transcript - GuruFocus
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Truist Financial - MarketBeat
Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge - Yahoo Finance
Advanced Cell-based Therapy Booming the Success for Healthcare Sector - Sahm
Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings? - sahmcapital.com
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference - simplywall.st
Iovance Biotherapeutics Announces Upcoming Board Member Retirement - The Globe and Mail
Iovance Biotherapeutics board member Wendy Yarno to retire after current term - Investing.com
Form 8K Iovance Biotherapeutics Inc For: 20 March - Investing.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting - Stock Titan
Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Zacks Research Issues Optimistic Forecast for IOVA Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeu - The National Law Review
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) latest press releases and corporate news - Yahoo Finance Singapore
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics (IOVA) Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational TrialWhat's Changed - Sahm
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma - MSN
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas - Yahoo Finance
Iovance Biotherapeutics (IOVA) announces positive early data for lifileucel TIL therapy in advanced sarcomas - MSN
Iovance Biotherapeutics Takes Steps Amidst Market Dynamics - timothysykes.com
What's going on with Iovance Biotherapeutics stock on Friday? - MSN
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook - StocksToTrade
Iovance Biotherapeutics Faces Challenging Market Dynamics Amidst Financial Strain - timothysykes.com
Iovance Biotherapeutics Inc (IOVA) Stock Price, Trades & News - GuruFocus
IOVANCE (NASDAQ: IOVA) CFO awarded 132,200 RSUs in equity grant - Stock Titan
235,000 RSUs granted to Iovance (NASDAQ: IOVA) interim CEO Frederick Vogt - Stock Titan
Equity grant: IOVANCE (NASDAQ: IOVA) awards 117,500 RSUs to Chief Regulatory Officer - Stock Titan
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):